Chronic heroin use disorder and the brain:current evidence and future implications by Tolomeo, Serenella et al.
                                                                    
University of Dundee
Chronic heroin use disorder and the brain
Tolomeo, Serenella; Steele, J. Douglas; Ekhtiari, Hamed; Baldacchino, Alex
Published in:









Link to publication in Discovery Research Portal
Citation for published version (APA):
Tolomeo, S., Steele, J. D., Ekhtiari, H., & Baldacchino, A. (2020). Chronic heroin use disorder and the brain:
current evidence and future implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry,
[110148]. https://doi.org/10.1016/j.pnpbp.2020.110148
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Dec. 2021
Heroin use disorder and the brain: current evidence and future implications 
1 
Chronic heroin use disorder and the brain: current evidence and 
future implications 
S. Tolomeo1*, J. Douglas Steele2, H. Ekhtiari3, A. Baldacchino4 
1 Department of Psychology, National University of Singapore (NUS), Singapore. 
2 School of Medicine, University of Dundee and Department of Neurology, NHS Tayside, 
Ninewells Hospital and Medical School, UK. 
3 Laureate Institute for Brain Research (LIBR), Tulsa, OK, USA. 
4 Division of Population and Behavioural Sciences, University of St Andrews, Fife, 
Scotland, United Kingdom. 
Abstract Words: 217 
Total Words: 4539 
Tables: 1 
Key words: 8 
Keywords: chronic  heroin use, neurocognition, neuroimaging, fMRI, opiate, sMRI, 
neurology, interventions. 
Corresponding author: 
Serenella Tolomeo,  
Department of Psychology, 
National University of Singapore (NUS), 
Email: fasst@nus.edu.sg 
Manuscript File Click here to view linked References
© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/




The incidence of chronic heroin use disorder, including overdose deaths, has 
reached epidemic proportions. Here we summarise and evaluate our knowledge of 
the relationship between chronic heroin use disorder and the brain through a 
narrative review. A broad range of areas was considered including causal 
mechanisms, cognitive and neurological consequences of chronic heroin use and 
novel neuroscience-based clinical interventions. Chronic heroin use is associated 
with limited or very limited evidence of impairments in memory, cognitive 
impulsivity, non-planning impulsivity, compulsivity and decision-making. 
Additionally, there is some evidence for certain neurological disorders being 
caused by chronic heroin use, including toxic leukoencephalopathy and 
neurodegeneration. However, there is insufficient evidence on whether these 
impairments and disorders recover after abstinence. Whilst there is a high 
prevalence of comorbid psychiatric disorders, there is no clear evidence that 
chronic heroin use per se causes depression, bipolar disorder, PTSD and/or 
psychosis. Despite the growing burden on society from heroin use, knowledge of 
the long-term effects of chronic heroin use disorder on the brain remains limited. 
Nevertheless, there is evidence for progress in neuroscience-based interventions 
being made in two areas: assessment (cognitive assessment and neuroimaging) 
and interventions (cognitive training/remediation and neuromodulation).  
Longitudinal studies are needed to unravel addiction and neurotoxic mechanisms 
and clarify the role of pre-existing psychiatric symptoms and cognitive 
impairments. 
Keywords: fMRI, heroin, neurocognition, neuroimaging, neuroscience, sMRI, 
neurology, interventions. 





This review aims to summarise current knowledge of chronic heroin use disorder 
with regard to the brain and highlight areas of progress. A characteristic feature of 
chronic heroin use disorder includes a strong desire to use opioids, manifested by 
an impaired ability to control use despite harm and negative consequences 
(American Psychiatric Association, 2013). 
By conceptualizing heroin use disorder as a chronic brain disorder, clinicians 
can better understand the course and treatment of its many complications, how to 




The increasing incidence of opioid use disorder, including overdose deaths, 
has reached epidemic proportions (Kreek et al., 2019). About 275 million people 
worldwide, 5.6 per cent of the global population aged 15–64 years), used drugs at 
least once during 2016 (World Drug Report, 2019). Amongst these were about 34 
million people who used opioids and about 19 million who used opiates. Roughly 
450,000 people died as a result of drug use in 2015 and those deaths (Larochelle et 
al., n.d.).  The lifetime prevalence of witnessed overdoses among drug users is about 
70%. The US  has the highest prevalence of opioid use, near to 4 per cent of the 
population aged 15–64 (World Drug Report, 2019). About 2.1 million Americans 
have opioid use disorder and opioids were involved in more than 47,600 deaths in 
2017 in the US accounting for more deaths than road traffic accidents and gun 
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violence combined (Rudd et al., 2016). Over 4.3 million Americans are engaged in 
non-medical use of prescription opioids per month and 4.8 million people have used 
heroin at some point in their lives. From each year since 2002, estimates of past 
month heroin use, past year heroin use, and opioid (heroin) use disorder have 
increased amongst 18-25 year old (“Data Overview | Drug Overdose | CDC Injury 
Center,” n.d.). 
Approximately two-thirds of current people who primarily use heroin 
additionally use prescription opioids and there is evidence that the first opioid 
abused is most frequently a prescription opioid rather than heroin, as was the case 
in the 1960s through 1980s (Philips and Ford, 2017). Heroin use is increasing for 
persons who begin by first having non-medical use of opioid analgesics. Illicit use 
of fentanyl, a highly potent synthetic opioid often used to “cut” heroin, has 
increased in the United States, contributing to a very substantial rise in fatal 
overdoses (Larochelle et al., 2018).   
There have been steps taken at a global level to set strategies for a response 
to this grave situation, particularly over the past decade. The Joint UN Ministerial 
Political Declaration and Plan of Action in 2014 (Commission on Narcotic Drugs 
opens its 57th session in Vienna) explicitly reaffirmed that SUD is a health problem 
with a need to further strengthen public health systems that are responsive to current 
and emerging drug-related problems. The adoption of the Sustainable Development 
Goals also reaffirms this vision of strengthening the prevention and treatment of 
substance abuse, including narcotic drug abuse and harmful use of alcohol. The 
outcome document of the special session of the United Nations General Assembly 
on the World Drug Problem held in 2016 (UNGASS, 2016) contains more than 100 
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recommendations for promoting evidence-based prevention, care and other 
measures to address both supply and demand. Additionally, WHO and UNODC 
have developed a close collaboration to support the implementation and 
development of comprehensive, integrated health-based approaches to drug 
policies, that can reduce demand for illicit substances, relieve suffering and 
decrease drug-related harm to individuals, families, communities and societies 




3. Clinical presentation of chronic heroin use 
 
3.1. Neuroadaptation ad impairment 
 
The term chronicity describes the repeated administration of opioid drugs 
with the adaptive mechanisms changing the functioning of opioid-sensitive neurons 
and neural networks perhaps in an irreversible or hard-to-reverse manner (Christie, 
2008). Neuro-adaptation is particularly a consequence of sustained mu receptor 
stimulation by opioid drugs (Kieffer and Evans, 2002).  Hallmarks of 
neuroadaptations to chronic opioid use are: 
 Tolerance, defined as reduced sensitivity to acute opioid effects (e.g. 
euphoriant and analgesic effects);  
 Physiological manifestations of opioid withdrawal on abstinence;  
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 Drug craving and attention directed towards drug-seeking and drug 
intoxication.  
Neuroadaptations following chronic heroin exposure extend well beyond 
reward circuits to other brain systems, notably those involved in cognition and 
stress responses (Koob and Volkow, 2016). Important brain regions affected 
include the amygdala, hippocampus and cerebral cortex and their connections to 
the nucleus accumbens.  Cognitive maladaptation is an umbrella term for any 
“neuroadaptation” resulting from extreme saliency (importance or value) of drug 
reward. High sensitivity to short term reward and preferred attention to drug-related 
cues are some examples of cognitive maladaptation in substance users that could 
be potentially be addressed using cognitive 2 
 
3.2. Neurocognitive impairments 
 
As above, opioids have been associated with a number of neuropsychological 
impairments during both chronic use and after a period of abstinence (Verdejo-
García and Pérez-García, 2007). Neuropsychological studies of chronic opioid 
users have identified deficits in executive functions. including impairments in 
cognitive flexibility (Pirastu et al., 2006), strategic planning (Ersche et al., 2006; 
Ersche and Sahakian, 2007), decision making (Verdejo-García et al., 2007; 
Verdejo-García et al., 2007) and inhibitory control (Mintzer et al., 2005). However 
other studies found no clear deficits when comparing the performance of healthy 
controls, with that of opioid abstinent, polysubstance users, head injury patients or 
patients with chronic pain (Jamison et al., 2003). 
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The accumulated literature tends to assume that neuropsychological function 
is to some extent impaired as a consequence of chronic opioid use and that the 
impairments are different from that seen in acute and sub-acute users (Zacny, 1995). 
Meta-analytical research has shown that chronic heroin use is associated with 
moderate deficits in verbal fluency, verbal working memory, inhibitory control, 
planning and risk and reward-based decision-making (Baldacchino et al., 2012). 
More recent studies have revealed visual memory, working memory impairments, 
impulsivity and compulsivity among chronic heroin users, including those enrolled 
in MMT and abstinent formerly dependent patients (Baldacchino et al., 2015; 
Tolomeo et al., 2019, 2018, 2016). MMT has generally been associated with 
additional cognitive impairments, although the specific cognitive domains which 
are affected remain unclear and may be explained by generalised cognitive slowing, 
affecting speed of information processing across different tasks, not as specific 
cognitive deficits (Baldacchino et al., 2012). Interestingly, buprenorphine seems to 
be a much “cleaner” drug with regard to neuropsychological test results, with most 
studies showing decision-making improvement relative to MMT associated with 
buprenorphine treatment (Baldacchino, Steele,  Davey, Tolomeo, 2019). 
Although research in this area is limited, it seems to point to a general 
improvement in at least some areas of neuropsychological functioning after at least 
2 weeks of abstinence from heroin use. This suggests that some of the impairments 
observed in active heroin users are transient effects of intoxication by the drug 
itself. In one observational study by Baldacchino et al. (Baldacchino et al., 2015) 
and three studies by Tolomeo et al. (Tolomeo et al., 2019, 2018, 2016),  abstinent, 
previously heroin-dependent individuals showed significantly higher cognitive and 
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non-planning impulsivity, and impaired flexibility and visuospatial memory when 
compared with healthy controls. Longitudinal studies are however required to 
clarify this issue. 
 
3.3. Psychiatric Illness 
 
Many studies have found a significant prevalence of depression, anxiety 
and/or Post-Traumatic Stress Disorder (PTSD) in individuals with heroin use 
disorders which is also associated with worse treatment outcome and prognosis. 
These findings suggest the importance of identifying and treating psychiatric 
disorders among heroin-dependent individuals, since the effective treatment of 
psychiatric co-morbidity potentially improves prognosis for heroin use disorder  
(Hasin et al., 2004; Hassan et al., 2017). However, there is no clear evidence to 
support the hypothesis that heroin use, per se, increases the risk of these psychiatric 
disorders through possible molecular and/or cellular pathways. Similarly, a direct 
relationship between opioid use and psychosis including schizophrenia is unclear. 
Theoretically though, as chronic opioid use is associated with D2 receptor reduction 
similar to other addictive substances (G J Wang et al., 1997). if abstinence is 
associated with enhanced D2 receptor function, psychosis might occur.  
Animal models indicate that early-life stress results in long-term changes in 
stress responses which can alter the sensitivity of the dopamine system and increase 
susceptibility to self-administration of substances of abuse (Koob and Schulkin, 
2018). While it is difficult to systematically delineate the specific neural basis of 
comorbidity, these studies provide potential pathways to explore in attempting to 
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understand the well-established relationship between early-life adversity, 
psychiatric disorders and opioid use disorders in adolescents and adults (Suh and 
Ressler, 2018). 
 
3.4. Cerebrovascular Disease 
 
Opioids do not elevate blood pressure; indeed they can cause bradycardia 
and vasodilation and so may lead to hypotension and tend not to directly increase 
the risks of developing an ischaemic or haemorrhagic stroke. Indeed, repeat dose 
opioids may be used therapeutically to treat breathlessness in chronic heart failure 
(Oxberry et al., 2013).  However long-term opioid use may aggravate the risk of 
cardiovascular disease by elevating low-density lipoproteins and free triglycerides; 
these biochemical hallmarks are associated with an increased risk of 
atherosclerosis, cerebrovascular ischemia, and myocardial infarction. 
 Particularly relevant to heroin users, the use of non-sterile opioids can 
substantially increase the risk of ischemic events (Radke et al., 2014). Non-sterile 
syringes/equipment facilitates the entry and dissemination of organisms into the 
bloodstream when taking heroin which can cause infarcts. Severe damage to 
peripheral veins is often particularly noticeable in long-term heroin users.  Illicit 
opiates very often contain contaminants and bacteria, septicaemia and endocarditis 
are increased in opioid use disorder (Kovacs et al., 2015). Infective emboli may 
occlude cerebral vessels causing necrosis and stroke. septic arteritis and aneurysm 
causing intracranial haemorrhage have been reported. Compounding these events 
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is the increased risk of non-fatal overdoses and consequent hypoxic cerebral 
damage (Hassan et al., 2019; Pearson et al., 1976; Trescot et al., 2008).  
 
3.5. Other Neurological Diseases 
 
Toxic leukoencephalopathy is a progressive degeneration of the myelin in 
the white matter which has been reported in opioid users although the pathological 
mechanism remains unclear (Achamallah et al., 2019). Patients may present with 
inattention, changes in personality, dysarthria, ataxia, dementia, coma and even 
death. Pronounced, confluent, subcortical white matter changes are characteristic 
MRI appearances correlate with degeneration of the deep white matter and axonal 
damage on postmortem examination.  However, due to its rarity, there is no 
systematic case series published as yet. An increase in the number and distribution 
of hyperphosphorylated tau-positive neurofibrillary pre-tangles has been noted in 
populations of young, chronic heroin abusers (Kovacs et al., 2015a). Chronic opioid 
use is also is associated with neurodegeneration, such as reports of occasional 
ubiquitin-positive neurons (Kovacs et al., 2015). Consistent with these pathological 
findings, significant brain atrophy has been recognised in heroin abusers.  Detailed 
understanding of the relationship between these neurological abnormalities and the 
development of cognitive impairments remains unclear.  Lesions in the globus 
pallidus are a long-recognized consequence of heroin use and are thought to be 
related to hypoxic injury (Pearson et al., 1976). Other reported neurological disease 
includes aseptic and septic (bacterial, viral and fungal) meningitis and cerebral 
abscesses (Risdahl et al., 1998), A review proposed that opiates alter host defences 
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against infectious disease agents, affected by opioid administration, severity of 
dependence and dose and route of infection (Risdahl et al., 1998). 
 
4. Pharmacology of chronic heroin use 
 
Opioids act by attaching to three types of receptor; mu, delta, and kappa.  
These are found both pre- and post-synaptically on neurons predominately within 
the nucleus accumbens, amygdala and cerebral cortex of the brain. They regulate 
responses to pain, but also exert effects on satiety, thirst and respiratory 
drive.  The euphoric effects of opioids are thought to arise chiefly via activation of 
mu-opioid receptors and dysphoric effects by activation of kappa opioid receptors, 
whereas the analgesic effects are thought to arise via activation of mu, kappa and 
delta receptors.  Drugs that stimulate mu-opioid receptors increase the firing of 
dopaminergic neurons in the ventral tegmental area of the midbrain (Fields and 
Margolis, 2015). These dopaminergic neurons project widely to other parts of the 
brain, particularly the basal ganglia including the accumbens and the prefrontal 
cortex.  In medicine, causal mechanisms are generally studied using animals. It is 
usually not possible to establish causal mechanisms in a study on humans because 
of ethical limitations. However, neuroimaging studies in humans can be used to test 
whether measures obtained non-invasively are consistent with causal mechanisms 
hypothesized from studies on animals. 
 
4.1. Functional Neuroimaging 
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Whilst there is significant experimental evidence implicating the endogenous 
opioid system (opioid peptides and opioid receptors) with the processes of reward 
and reinforcement, the functional neuroimaging evidence in clinical populations is 
limited. Regarding fMRI, most task-based fMRI studies have explored drug/stress 
cue-reactivity paradigms (Langleben et al., 2008; Tabatabaei-Jafari et al., 2014; 
Wang et al., 2011) and only a few have explored response control and decision-
making paradigms to investigate hypothesised brain region or network dysfunctions 
in people with heroin use disorder. For example, Gradin and colleagues reported 
disrupted reward processing within the striatum and increased sensitivity to 
aversive events within the amygdala and hippocampus in patients receiving 
Methadone Maintenance Therapy (MMT) (Gradin et al., 2014). In the same study, 
the authors reported blunted striatal reward prediction error signals, which can be 
considered a ‘signature’ of dopamine system activity (Gradin et al., 2014). A recent 
systematic review concluded that heroin use is associated with weak fronto-
cingulate connectivity with subcortical regions, but strong functional connectivity 
with the amygdala and striatum (Stewart et al., 2019). Preliminary evidence 
suggests that functional brain abnormalities within the inferior frontal cortex and 
anterior cingulate cortex may improve as a function of long-term heroin abstinence 
(Goldstein and Volkow, 2011). 
 
4.2. Structural Neuroimaging 
 
Grey matter consists of cell bodies, dendrites and synapses that process 
information in cortical and subcortical brain regions. Brain white matter consists of 
Heroin use disorder and the brain: current evidence and future implications                                                   
13 
 
myelinated axons that connect grey matter regions. Studies using sMRI have 
revealed that heroin use is associated with grey matter and white matter reductions, 
in the striatum, fronto-cortical and cingulate regions, and amygdala and insula 
(Denier et al., 2013; Liu et al., 2009; Yuan et al., 2009).  Additionally, longer opioid 
use has been reported to be associated with greater grey and white matter reductions 
in heroin users (Forman et al., 2004; Liu et al., 2009; Yuan et al., 2009). Structural 
magnetic resonance imaging studies of human opioid-dependent populations have 
revealed significant grey matter reductions in the prefrontal and temporal cortices 
(Liu et al., 2009; Lyoo et al., 2006; Yuan et al., 2009) and increased white matter 
hyper-intensities, mainly in frontal areas (Lyoo et al., 2004). 
Notably, these brain structure abnormalities are located in neural 
regions/networks associated with executive and attentional cognitive functions, 
such as the dorsolateral prefrontal cortex, anterior cingulate cortex and medio-
temporal cortices. Chronic heroin-dependent individuals have been reported to 
show grey matter reductions in the left gyrus and cingulate gyrus within three days 
of abstinence (Wang et al., 2012). However, after one month of abstinence, there 
were no significant differences between patients and controls in any structural brain 
region (Wang et al., 2012). The mechanisms of this short-term change are unknown 
and studies on animals would be required to test whether abstinence was causal and 
reflected actual brain structure changes, or indirect changes (e.g. short-term 
changes in brain hydration due to a change in fluid intake during initial abstinence).  
Another study by Tolomeo et al., 2016 reported that MMT patients exhibited 
extensive grey matter reductions in the orbito-medial prefrontal cortex, bilateral 
caudate nucleus and globus pallidus (Tolomeo et al., 2016). Similarly, Tolomeo et 
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al., 2018 reported reduced white matter integrity in MMT individuals in comparison 
to healthy controls (Tolomeo et al., 2018). This is an empirical finding and the 
causal mechanisms are unknown, although direct and indirect effects of heroin use 
appear likely.  In addition, as the study reported by Tolomeo and colleagues was 
cross-sectional, subjects at higher risk of developing opioid dependency may have 
reduced grey and white matter before exposure to opioids or abnormalities might 
reflect multiple episodes of hypoxia, e.g. occurring at night and during a respiratory 
infection, especially if additional illicit opioids and/or alcohol have been used to 
‘top-up’ MMT. Longitudinal neuroimaging studies on patients and studies on 
animals would be required to test these hypotheses.  In that context, it’s important 
to note that most neuroimaging evidence is based on measures of brain structure or 
function in cross-sectional studies. We suggest that longitudinal studies are crucial 
to evaluate causality. Similarly, incentive salience deficits and deficits in reward 
processing (Koob and Volkow, 2016) might be driven by pre-existing vulnerability 
factors and by other environmental factors (e.g. peer pressure,  stress and ready 
availability of drugs). Table 1 provides a summary of the long-term effects of heroin 
use on brain structure, cognition, psychiatric comorbidities and neurological 
disorders.  
 
4.3. PET Studies 
 
PET imaging studies by Volkow have reported a reduction in striatal 
dopamine D2 receptors (Volkow et al., 2002)which may be consistent with causal 
drug administration studies on animals (Volkow et al., 2002) and there are very 
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few studies of the opioid system in humans.  D2 receptors play a crucial role in 
the motivational component of heroin addiction and chronic heroin use revealed 
changes in D2 receptor availability as shown by previous studies. Wang and 
colleagues reported that D2 receptor availability was lower than in controls (Gene 
Jack Wang et al., 1997). These findings were confirmed later by Zijlstra and 
colleagues who revealed lower baseline availability of D2 receptor in abstinent 
individuals (Zijlstra et al., 2008). In summary, this low availability of D2 
receptors might play a role in the pathophysiology of addiction and relapse (Koob 
and Volkow, 2016). 
 
 
4.4. Postmortem brain studies 
 
Previous postmortem brain studies in chronic heroin users revealed 
elevated striatal levels of 5HT, whereas serotonin metabolite 5-
hydroxyindoleacetic acid was significantly decreased compared to controls (Kish 
et al., 2001). Also, the same study found no difference in striatal dopamine (DA) 
transporter levels between chronic heroin users and controls (Kish et al., 2001). In 
addition, a post-mortem study of opioid-dependent individuals reported an 
increased prevalence of ischaemic brain lesions in the globus pallidus thought to 
be a specific effect of opioid-induced hypoxia (Andersen and Skullerud, 1999). 
Notably, lesions in the globus pallidus are a long-recognized consequence of 
heroin use and are thought to be related to hypoxic injury (Pearson et al., 1976). 
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5. Future directions: new hopes for treatment with clinical translation and 
implementation neuroscience 
 
Available treatment options for opioid use disorder are limited in efficacy 
(Volkow, 2018) so the likelihood of returning long-term to normal life is limited. 
Whilst there is a clear consensus regarding neurobiological and neuropsychological 
abnormalities related to individuals with opioid use disorder, application of recent 
advances in neuroscience to clinical practice is rarely promoted (Verdejo-Garcia et 
al., 2019). We cover in the next section new directions that neuroscience-based 
interventions can bring to the treatment of opioid use disorder. 
 
5.1. Pharmacological interventions 
 
The FDA and other similar agencies globally have approved three 
medications for Heroin Use Disorder, namely Methadone, Naltrexone, and 
Buprenorphine; however, there is a clear need for new medications with higher 
treatment adherence, retention, lower abstinence rates and side effects (Kleber, 
2007). Clinical trials using clinical outcome assessments (COAs) in drug addiction, 
such as urine drug tests, need large scale trials with long-term follow up and do not 
capture all relevant aspects of recovery or lack of it. Responding to this need, there 
is a new movement to apply neuroscience-based approaches that are reliable, 
sensitive to acute treatment response, and valid for addressing illness mechanisms 
involved in chronic heroin use disorder (Verdejo-Garcia et al., 2019). Targeting 
cognitive processes impaired in heroin using populations, such as self-control and 
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executive function with pharmacological interventions for cognitive enhancement, 
is another line of neuroscience research which may enhance the efficacy of existing 
medications (Verdejo-Garcia et al., 2019). 
 
5.2. Cognitive interventions 
 
With recent advances in the cognitive neuroscience and cognitive 
psychology of opioid use disorder, one can start to postulate how neuroscience can 
inform new generation of cognitive interventions to become an adjunct to current 
clinical practice. Few examples of the neuroscience-informed cognitive 
interventions and their preliminary evidence in substance use disorders in general 
and opioid use disorder in specific are summarized below into three main 
categories:  
 
(a) Neuroscience-informed Psychoeducation and Metacognitive Training: 
Metacognition is thinking about one’s thoughts.  Poor metacognitive functioning 
relates to reduced consistency between subjective symptoms and real objective 
states (e.g. self-report craving and actual arousal states) (Castine et al., 2019) denial 
of problems associated with drug use (Moeller and Goldstein, 2014) and decreased 
interoceptive sensations (generated within the body) or awareness (Ateş Çöl et al., 
2016). Accordingly, different interventions may enhance metacognition for opioid 
users. This includes ‘motivational interviewing’, which may enhance 
metacognition through improvements in insight and motivation for change 
(Apodaca and Longabaugh, 2009) as well as neuroscience-informed 
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psychoeducation programs aiming to improve a subject’s awareness about their 
own mental health disorder and brain-related problems. Rezapour, et al., 2020, 
reported the feasibility and preliminary efficacy of a neuroscience informed 
psychoeducation intervention in a mixed group of opioid and meth users to improve 
metacognitive awareness (Rezapour et al., 2020) however, the evidence for long 
term efficacy of these interventions among opioid users is still missing. 
 
(b) Neuroscience Informed Cognitive Modifications: The Cognitive Behavioural 
Therapy (CBT)-based model (Beck, 1979) for substance use disorders involves four 
main elements: triggers, thoughts/affect, craving and drug use (Larimer et al., 2003; 
Oei et al., 1991). In a cognitive neuroscience-informed approach, thoughts and 
craving can be delineated into 5 major cognitive processes, namely, attention, 
saliency valuation, memory, interoception and executive control. Each of these 
cognitive processes can be modified by cognitive interventions aimed at changing 
the cognitions elicited by drug/stress cue exposure to prevent relapse (Ekhtiari et 
al., 2017). As an example, attentional bias modification interventions have shown 
some promising results and some negative findings in modulating drug craving 
among substance users, however, there still a gap on rigorous studies in opioid use 
disorder (MacLean et al., 2018). 
(c) Neurocognitive Rehabilitation: Neuropsychological (cognitive) impairments 
can interfere with treatment by reducing the ability of a user to receive, encode, 
integrate and employ therapeutic strategies, both in the context of treatment 
sessions and their everyday lives  (Rezapour et al., 2016). There is a growing 
body of evidence for the effect of cognitive rehabilitation on attention, working 
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memory and executive functions to improve relapse rate among people with 
opioid use disorder (Rezapour et al., 2019). 
 
5.3. Technology-based Neuromodulation Interventions 
 
Different neuromodulatory interventions including non-invasive brain 
stimulation technologies and neurofeedback have shown preliminary but promising 
results in treatment of opioid use disorder. Neurofeedback is a technique that helps 
patients to modulate their brain activity into a target state. Real-time brain activity 
is represented as visual or auditory feedback (e.g. a car driving on the road with 
speed related to the brain activity) and patients learn to change their brain activity 
from an undesired state to a desired state and monitor the results through feedback 
(e.g. changing the speed of the car). These practices can include not thinking about 
drug-related memories and/or remembering happy memories instead. Two types of 
neurofeedback have been used to in opioid use disorder; EEG and fMRI 
neurofeedback, which differ in the type brain measurements; i.e., the activity of a 
brain region/network of interest with fMRI and recorded electrical activity from a 
set of electrodes in EEG. Psychological and behavioural improvements have been 
reported in substance use disorders (SUDs) treated by EEG or fMRI neurofeedback: 
amongst 15 studies (7 for EEG and 8 for fMRI) that investigated the effects of 
neurofeedback (EEG or fMRI) on SUDs reported up until July 2019, two studies 
used EEG-neurofeedback, reporting that this technique had positive outcomes on 
opioid use disorder (Luigjes et al., 2019; Verdejo-Garcia et al., 2019). The first 
study published in 2010, used 30 sessions of neurofeedback with 20 opioid-
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dependant patients and reported a significant reduction in heroin craving (Arani et 
al., 2010). In the following study by the same group, the same protocol with 
different targets resulted in improvement in somatic symptoms of drug use, mood, 
and a total score reflecting general mental health, with a reduction in anticipation 
of positive outcome and desire to use opioids, and some relief from withdrawal of 
craving (Dehghani-Arani et al., 2013). These studies are preliminary and much 
more work would be required to develop an effective widely available service for 
people with opioid use disorder. 
Over 80 clinical trials with transcranial Electrical Stimulation (tES) and 
Transcranial Magnetic Stimulation (TMS) have been reported although very few of 
them on opioid use disorder (Verdejo-Garcia et al., 2019).  This suggests a 
possibility for using such techniques as an adjuvant to conventional addiction 
treatments, to reduce drug craving, improving cognitive control, and mitigating 
withdrawal negative affect (Ekhtiari et al., 2019). A recently published tES study 
(reported that anodal transcranial direct current stimulation (tDCS) to the right 
dorsolateral prefrontal cortex significantly reduced drug craving, depression, and 
anxiety symptoms amongst people with opioid use disorder (Taremian et al., 2019). 
In another study by Wang et al., 2016, bilateral tDCS over frontal and 
temporoparietal regions reduced craving scores in heroin users (Wang et al., 2016). 
In another trial, Shen et al. reported that a single session of 10 Hz repetitive TMS 
over the left dorsolateral prefrontal cortex reduced cue-induced craving in heroin 
users (Shen et al., 2016). A few years later, the same group reported that use of a 
similar TMS protocol in multiple sessions improved sleep quality and low 
mood/increased anxiety among a mixed group of opioid and methamphetamine 
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users (Lin et al., 2019). However, these studies are still preliminary and clear 
demonstration of the presence or absence of any clinically meaningful effects on 




Despite the growing global burden of opioid use disorder, knowledge of the 
long-term brain effects of heroin use disorder is limited. Although there is a 
consensus that altered brain structure and function may underpin opioid use 
disorder, clinicians working in addiction treatments centres rarely incorporate 
neuroscience-informed approaches into their practice. This article has summarised 
key priorities and strategies to facilitate such incorporation including summarising 
addictions neuroscience-based understanding and highlighting tools for the 
assessment and treatment of heroin use disorder. Two assessment areas have been 
highlighted: cognitive assessment and neuroimaging, and two interventional areas: 
cognitive training/remediation and neuromodulation. Integration of neuroscience-
based approaches can be best achieved by promoting international collaboration 
between researchers and clinicians, developing harmonised protocols and data 
management systems, and prioritising multi-site research that focuses on improving 
clinical outcomes (Verdejo-Garcia et al., 2019). Future longitudinal studies are 
required to unravel the mechanisms of action and role of co-existing psychiatric 
disorders and cognitive impairments.  
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